Kathryn Zoon - EMERGENT BIOSOLUT Independent Director
| ER4 Stock | EUR 5.25 0.08 1.50% |
Director
Dr. Kathryn C. Zoon, Ph.D., is Independent Director of the Company. Dr. Zoon is currently NIAIDNIH Scientist Emeritus, a position she has held since August 2016. From April 2016 to June 2016, she was Interim Director of the new NIH Office of Research Support and Compliance where she developed and established the new office and recruited key individuals to continue its future operations. She was also Chief of the Cytokine Biology Section in the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH until July 2016, where she conducted research on the structure and function of human interferon alphas and developed a new cell therapy using IFNs and autologous monocytes which she is still collaborating with the National Cancer Institute to start a clinical trial for ovarian cancer. She was previously the Director of the Division of Intramural Research at NIAID from 2006 August 2015 and was the Deputy Director for Planning and Development of the Division of Intramural Research at NIAID, 20042006. Dr. Zoon served as the Principal Deputy Director of the Center for Cancer Research at the National Cancer Institute, 20032004. She served as the Director of the Center for Biologics Evaluation and Research, Food and Drug Administration, and was a member of the NIH Scientific Directors from 1992 to 2015 since 2016.
| Age | 70 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
Kathryn Zoon Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kathryn Zoon against EMERGENT BIOSOLUT stock is an integral part of due diligence when investing in EMERGENT BIOSOLUT. Kathryn Zoon insider activity provides valuable insight into whether EMERGENT BIOSOLUT is net buyers or sellers over its current business cycle. Note, EMERGENT BIOSOLUT insiders must abide by specific rules, including filing SEC forms every time they buy or sell EMERGENT BIOSOLUT'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kathryn Zoon over six months ago Disposition of 10000 shares by Kathryn Zoon of Emergent Biosolutions at 6.11 subject to Rule 16b-3 | ||
Kathryn Zoon over six months ago Disposition of 1830 shares by Kathryn Zoon of Emergent Biosolutions at 4.61 subject to Rule 16b-3 |
Similar Executives
| Found 10 records | DIRECTOR Age | ||
| Qi ZHOU | COFCO Joycome Foods | 34 | |
| Jiandong Ju | COFCO Joycome Foods | 56 | |
| Juhui Huang | COFCO Joycome Foods | 51 | |
| Ted Lee | COFCO Joycome Foods | 66 | |
| Guiyong Cui | COFCO Joycome Foods | 53 | |
| Julian Wolhardt | COFCO Joycome Foods | 46 | |
| Hankin Li | COFCO Joycome Foods | 55 | |
| Lei Zhang | COFCO Joycome Foods | N/A | |
| Tingmei Fu | COFCO Joycome Foods | 54 | |
| Hong Yang | COFCO Joycome Foods | 54 | |
EMERGENT BIOSOLUT Leadership Team
Elected by the shareholders, the EMERGENT BIOSOLUT's board of directors comprises two types of representatives: EMERGENT BIOSOLUT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EMERGENT. The board's role is to monitor EMERGENT BIOSOLUT's management team and ensure that shareholders' interests are well served. EMERGENT BIOSOLUT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EMERGENT BIOSOLUT's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Sean Kirk, Executive Vice President Manufacturing and Technical Operations | ||
| Katherine Strei, Executive Vice President, Human Resources and Communications, Chief Human Resources Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Marvin White, Director | ||
| Kathryn Zoon, Independent Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Adam Havey, Executive Vice President and Presidentident - BioDefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Independent Director | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
EMERGENT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EMERGENT BIOSOLUT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.